Abstract
Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Reviews on Recent Clinical Trials
Title:Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Volume: 9 Issue: 2
Author(s): Reiner Buchhorn and Robert D. Ross
Affiliation:
Keywords: Beta-blockers, childhood, duchenne, heart failure, hypertrophic cardiomyopathy, sudden death.
Abstract: Heart failure remains the main cause of death in children with heart disease. In USA and Europe hospital mortality of children with heart failure is about 7% of children, nearly twice as high as in adults. In this review a group of authors report about their experience with beta-blockers in childhood heart failure. Most of them start to treat children with severe heart failure at a time - 20 years ago - when beta blockers seem to be contraindicated in this situation. The physicians and their patients and/or parents all are aware of the risk of this decision. However, unproven medical therapies for heart failure are the most important therapeutical dilemma in pediatric cardiology. The authors carefully observed a highly selected group of patients with the highest risk to die and had the patience to wait for the longtime follow up. Today - based upon this experience –we know that beta blockers are safe and may save the lives of many children with heart disease all over the world. Together with young colleagues who enthusiastically support this idea the authors now intend to break down the “wall of ignorance” for this promising therapy in pediatric cardiology.
Export Options
About this article
Cite this article as:
Buchhorn Reiner and Ross D. Robert, Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease), Reviews on Recent Clinical Trials 2014; 9 (2) . https://dx.doi.org/10.2174/157488710902141009103818
DOI https://dx.doi.org/10.2174/157488710902141009103818 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases
Current Gene Therapy Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes
Current Drug Discovery Technologies Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Cardiovascular & Hematological Agents in Medicinal Chemistry Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology EDITORIAL: Validation Techniques for Therapeutic Molecules in Drug Discovery
Current Topics in Medicinal Chemistry Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Pindolol Augmentation of Antidepressant Response
Current Drug Targets Cardiac Effects of Anabolic Steroids: Hypertrophy, Ischemia and Electrical Remodelling as Potential Triggers of Sudden Death
Mini-Reviews in Medicinal Chemistry Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
Current Medicinal Chemistry